Table 1. Mean IC50 values (with 95% confidence intervals) of melflufen and melphalan in 4 different AML cell lines (MV-4-11, HL60, Kasumi and KGI-A), AML patient samples and PBMCs from healthy donors.
| melflufen IC50 (μM) | melphalan IC50 (μM) | IC50 ratio | |
|---|---|---|---|
| MV4-11 | 0.018 (0.016-0.019) | 1.7 (1.4-2.0) | 94 |
| HL-60 | 0.13 (0.11-0.14) | 6.1 (5.5-6.9) | 47 |
| Kasumi | 0.082 (0.074-0.091) | 3.8 (3.3-4.5) | 46 |
| KG1-A | 0.17 (0.15-0.18) | 8.6 (7.1-10) | 51 |
| Patient samples | 0.067 (0.051-0.088) | 5.5 (4.7-6.5) | 82 |
| PBMC | 0.5 (0.30-0.85) | 9.7 (5.0-19) | 19 |
The ratio (melphalan/melflufen) describes magnitude of superiority.